Seroquel®
Quetiapine
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$1,200+ (brand Seroquel)
With Insurance
$10–30 (generic)
How It Works
Quetiapine is a "dirty" receptor drug — it blocks many different receptor types simultaneously. This explains both its therapeutic effects across multiple conditions AND why it causes such a wide range of side effects. At low doses (25–50mg), only the sedating H1 and alpha-1 receptors are meaningfully blocked — the antipsychotic D2 mechanism requires much higher doses.
Why the side effects happen
At 25–50mg (the off-label sleep dose), quetiapine primarily hits H1 and alpha-1 receptors. Weight gain and metabolic syndrome are largely H1-mediated. At therapeutic antipsychotic doses (400–800mg), the full receptor profile is engaged — explaining the extensive metabolic monitoring requirements. Tardive dyskinesia develops from D2 receptor supersensitivity after long-term D2 blockade.
When Will I Feel It?
Sedation occurs the first night. Antipsychotic and mood-stabilizing effects take weeks. The 25mg "sleep dose" works differently from the therapeutic antipsychotic dose — it acts on sedating receptors, not antipsychotic ones.
H1 blockade produces sedation — the reason it's prescribed for sleep. Dizziness and orthostatic hypotension common with first dose.
Sleep improvement or sedation effect established. Metabolic side effects (appetite increase) beginning.
Antipsychotic and mood stabilizing effects emerge for bipolar or schizophrenia at therapeutic doses.
Full antipsychotic response for schizophrenia. Ongoing metabolic monitoring required.
Adherence Note
The sedation you feel immediately is from H1 receptor blockade — not from the antipsychotic mechanism. If prescribed for sleep, you are essentially getting a potent antihistamine-like effect from a drug that carries the full metabolic, metabolic, and neurological risks of an antipsychotic.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Sedation / excessive drowsiness
57%Most common reason for prescribing — but also most common complaint. Next-day cognitive impairment is significant; avoid driving.
Weight gain
23%Average 5–7 lbs in first 12 weeks; ongoing with long-term use. Monitor BMI monthly.
Dry mouth
44%Stay hydrated; sugar-free gum helps. Increases dental cavity risk long-term.
Dizziness / orthostatic hypotension
18%Rise slowly from sitting or lying position. Dangerous in elderly — fall hazard.
Constipation
10%Increase fiber and water; anticholinergic effect. Can be severe with long-term use.
Elevated blood glucose / diabetes
5–10%Annual fasting glucose and HbA1c; especially important in those already at metabolic risk.
Elevated cholesterol/triglycerides
22%Annual lipid panel; diet modification and exercise mitigate this.
Serious Adverse Effects
- • Tardive dyskinesia — irreversible involuntary movements after long-term use; annual screening with AIMS scale is essential
- • Neuroleptic malignant syndrome (NMS) — rare but life-threatening: high fever, muscle rigidity, altered consciousness; requires emergency care
- • Black box warning: increased mortality in elderly patients with dementia-related psychosis
- • Metabolic syndrome — weight gain, diabetes, high triglycerides as a combined syndrome with long-term use
- • QTc prolongation — cardiac arrhythmia risk, especially at higher doses or with drug combinations
- • Agranulocytosis (rare) — monitor for infection signs, unusual fatigue
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Tardive dyskinesia — irreversible involuntary movements after long-term use; annual screening with AIMS scale is essential
- Neuroleptic malignant syndrome (NMS) — rare but life-threatening: high fever, muscle rigidity, altered consciousness; requires emergency care
- Black box warning: increased mortality in elderly patients with dementia-related psychosis
- Metabolic syndrome — weight gain, diabetes, high triglycerides as a combined syndrome with long-term use
- Severe nausea and vomiting
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Limited data. Neonatal extrapyramidal symptoms and withdrawal reported in 3rd trimester. Use only if benefit clearly outweighs risk; document the decision.
Excreted in breast milk. Infant sedation and developmental effects are a concern.
Low-dose quetiapine (25–50mg) is frequently prescribed off-label for sleep disruption during menopause — an application that was never tested in clinical trials at these doses. Declining progesterone is a primary driver of menopausal sleep problems; hormone therapy (particularly progesterone) may restore sleep without the metabolic and neurological risks of an antipsychotic.
FDA approved for schizophrenia (13+) and bipolar disorder (10+) only. Black box warning for increased suicidality. Off-label use in children for sleep, aggression, or anxiety is not supported and carries serious metabolic and neurological risks.
FDA black box: antipsychotics increase mortality risk in elderly patients with dementia-related psychosis. Beers Criteria lists quetiapine as high-risk in elderly. Falls, stroke, cognitive worsening.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
😴 Sleep Without Antipsychotics: CBT-I and Evidence-Based Alternatives
CBT for Insomnia (CBT-I) outperforms sleep medications at 12 months — and its effects are permanent, not just suppressed
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
CBT for Insomnia (CBT-I)
Strong6–8 sessions with a trained therapist
Gold standard per NIH and AASM. Superior to sleep medications long-term; effects persist after treatment ends. Should always be tried before any sleep medication.
Sleep restriction therapy
StrongCompress sleep window to actual sleep time; gradually expand
Core component of CBT-I; counterintuitive but highly effective at consolidating fragmented sleep within 2–4 weeks
Magnesium glycinate (300–400mg)
ModerateTake 30–60 minutes before bed
Activates GABA receptors; multiple RCTs show improved sleep onset and quality, especially in magnesium-deficient adults
Light therapy + circadian reset
ModerateBright light 10,000 lux at wake time; blackout curtains at night
Resets circadian rhythm — addresses the root cause of circadian-mismatch insomnia without drugs
Low-dose melatonin (0.5mg)
Moderate0.5mg taken 2hrs before desired bedtime
Most effective for sleep-phase issues; super-physiologic doses (5–10mg) are commonly sold but lower doses are more effective for signaling
How It Compares
Quetiapine causes more sedation and metabolic effects than most atypicals. Aripiprazole causes significantly less weight gain. Olanzapine causes more. For sleep specifically, quetiapine is not approved at any dose.
Strengths
- Effective for schizophrenia and bipolar
- Lower EPS risk than older antipsychotics
- Extended-release formulation for once-daily dosing
- Adjunctive depression data
Weaknesses
- Highest sedation burden of major atypicals
- Significant metabolic risk (weight, glucose, lipids)
- Black box warning: increased mortality in elderly dementia patients
- No approved sleep indication at 25mg
- Highest off-label prescribing rate of any antipsychotic
Clinically Preferred Alternatives
Global Prescribing & Pricing
United States
$30–80 (generic)/mo
Extreme off-label use for sleep — estimated 70%+ prescriptions are off-label
No mandatory psychiatric evaluation before prescribing; primary care physicians widely prescribe for sleep at 25mg. No national guidelines limiting off-label use.
Covered (generic)
United Kingdom
~$5–15/mo
Much more restricted; NICE mandates psychosis/bipolar indication
NICE guidelines: quetiapine only for schizophrenia and bipolar. Off-label sleep prescribing is discouraged and rarely done in primary care.
NHS covered with restrictions
Germany
~$10–25/mo
Lower off-label use; psychiatrist involvement typical
GKV covers only approved indications; off-label prescribing requires documented justification and usually specialist referral.
GKV with restrictions
Australia
~$20–40/mo
PBS restriction to approved indications limits off-label use
PBS subsidy requires approved indication; off-label sleep prescribing is not reimbursed.
PBS approved indications only
The US is an international outlier in off-label Seroquel prescribing for sleep. Other high-income countries require a documented psychiatric indication for reimbursement, effectively limiting the practice that generated AstraZeneca's $520M DOJ settlement.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
AstraZeneca paid $520 million in 2010 to settle federal and state charges for illegally promoting Seroquel for uses not approved by the FDA — including sleep disorders, aggression in elderly dementia patients, and depression in children. The DOJ settlement included $301M criminal fine. AstraZeneca had sales reps specifically target primary care physicians for off-label sleep prescribing at sub-therapeutic 25–50mg doses that were never tested in registration trials.
Declared Conflicts of Interest
Key opinion leaders who gave paid promotional talks for Seroquel were later found to have undisclosed financial relationships with AstraZeneca. Internal documents revealed AstraZeneca downplayed metabolic side effects (weight gain, diabetes) in marketing materials while privately tracking the "Seroquel metabolic problem."
Key Efficacy Results
FDA approved for schizophrenia, bipolar disorder, and adjunctive depression. Off-label use — particularly for sleep at 25–50mg — now accounts for an estimated 70%+ of prescriptions. The 25mg "sleep dose" has never been studied in an adequate RCT.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Quetiapine. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Quetiapine in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| CATIE Trial (NEJM 2005) | PMID:16172203 | |
| AstraZeneca $520M DOJ Settlement | DOJ-2010 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt quetiapine discontinuation causes rebound insomnia, anxiety, nausea, and vomiting — sometimes severe. After long-term use for psychosis, abrupt cessation can precipitate rapid relapse and psychotic crisis. The antipsychotic withdrawal syndrome is real and under-recognized.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe dose reduction of no more than 25–50mg every 2–4 weeks
- ·For high doses (>200mg), switching to a longer-acting formulation before reducing is documented in clinical literature
- ·Research supports slower dose reductions for long-term users or serious psychiatric conditions
- ·Research supports addressing underlying insomnia or anxiety with non-pharmacological approaches during the stopping process
- ·Published guidelines consistently recommend psychiatrist supervision for stopping if the medication was used for schizophrenia or bipolar disorder
Warning Symptoms — Contact Your Doctor If You Experience:
- Severe nausea and vomiting
- Return of psychotic symptoms (hallucinations, paranoia)
- Extreme insomnia lasting more than a few days
- Agitation or aggression significantly worse than baseline
- Suicidal thoughts
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.I was prescribed this for sleep — is there a specific FDA-approved sleep indication, or is this off-label at 25mg?
- 2.Has CBT for Insomnia (CBT-I) been offered to me as a first-line option before this prescription?
- 3.What is the plan for monitoring my blood sugar, cholesterol, and weight while I take this?
- 4.Am I at risk for tardive dyskinesia, and what would early signs look like?
- 5.What is the minimum dose and duration for my condition, and what is the exit plan?
Lab Tests to Request
- Fasting glucose and HbA1c (baseline + annually)
- Fasting lipid panel (baseline + annually)
- Weight and BMI monthly
- AIMS scale annually for tardive dyskinesia
- EKG if on other QT-prolonging medications
- Blood pressure (orthostatic) at baseline
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Seroquel®
- What is Seroquel® used for?
- Seroquel® (Quetiapine) is a Atypical Antipsychotic manufactured by AstraZeneca. FDA-approved indications include: Schizophrenia; Bipolar I disorder (mania); Bipolar depression; Adjunctive major depression (XR); Off-label: insomnia, anxiety, PTSD, dementia agitation.
- What are the common side effects of Seroquel®?
- Common side effects of Seroquel® include: Sedation / excessive drowsiness (57%); Weight gain (23%); Dry mouth (44%); Dizziness / orthostatic hypotension (18%); Constipation (10%).
- How much does Seroquel® cost?
- Seroquel® list price is approximately $1,200+ (brand Seroquel). With insurance it typically costs $10–30 (generic); without insurance approximately $30–80 (generic quetiapine).
- Who funded the clinical trials for Seroquel®?
- AstraZeneca paid $520 million in 2010 to settle federal and state charges for illegally promoting Seroquel for uses not approved by the FDA — including sleep disorders, aggression in elderly dementia patients, and depression in children. The DOJ settlement included $301M criminal fine. AstraZeneca had sales reps specifically target primary care physicians for off-label sleep prescribing at sub-therapeutic 25–50mg doses that were never tested in registration trials.
- How strong is the clinical evidence for Seroquel®?
- Key studies: CATIE trial (2005), multiple AstraZeneca-funded registration trials, off-label sleep/depression studies. FDA approved for schizophrenia, bipolar disorder, and adjunctive depression. Off-label use — particularly for sleep at 25–50mg — now accounts for an estimated 70%+ of prescriptions. The 25mg "sleep dose" has never been studied in an adequate RCT. Potential conflicts of interest: Key opinion leaders who gave paid promotional talks for Seroquel were later found to have undisclosed financial relationships with AstraZeneca. Internal documents revealed AstraZeneca downplayed metab.
- Are there non-drug alternatives to Seroquel®?
- CBT for Insomnia (CBT-I) outperforms sleep medications at 12 months — and its effects are permanent, not just suppressed See the Alternatives tab for full details.
Get notified when we update Seroquel®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.